

# **Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026**

<https://marketpublishers.com/r/PF0248FF7F35EN.html>

Date: September 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: PF0248FF7F35EN

## **Abstracts**

The Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

**Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast**

and outlook (2024-2031) Scope:

## Major Highlights

This report delivers a comprehensive overview of the Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement

and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### PEANUT ALLERGY THERAPEUTICS PIPELINE ANALYSIS

- Peanut allergy is one of the most common types of food allergies caused by a legume, known as peanut, which is common in children as well as adults.
- Peanut is an herbaceous plant that belongs to the family of legumes. It occurs when the body's immune system depicts an abnormal response for one or more peanut proteins. Individuals are suffering from this allergy exhibit symptoms such as itchy skin, an itching sensation around the mouth or throat, nausea, runny or congested nose, or anaphylaxis.
- The patients suffering from asthma and eczema are also been observed more likely to get the allergy from peanuts. Drop in blood pressure, swelling in the throat, fainting, and blockage of the airway can also occur in severe conditions.
- Even though the specific etiology of peanut allergy is not clear, it can because of the interaction of genetic susceptibility with environmental factors.
- The only available strategy currently for managing peanut allergy is the avoidance and the acute reactions treatment with parenteral epinephrine.
- An experimental peanut oral immunotherapy is prescribed to patients as an investigational treatment. These grassroots efforts can be effective in desensitizing patients to peanut, lack of regulatory agency approval and standardization, making it difficult to ensure the safety of the treatment.
- Many companies are developing drug candidates by using advanced technologies, and the drug candidates have known to show positive efficacy in the clinical and preclinical developmental stages.
- At present, there is no approved drug for the treatment of peanut allergy, leading to a large unmet need in its therapeutic pipeline. The first drug launcher has great benefits. This incredible growth stems from the expected entry of four new peanut immunotherapy products to fulfill the marketplace.
- These new therapies include three oral immunotherapy (OIT) products-Aimmune Therapeutics' AR-101, Camallergy's CA-002, Prota Therapeutics' PPOIT, and one epicutaneous immunotherapy product-DBV Technologies' Viaskin Peanut.
- The clinical studies analyzed that peanut allergy therapeutics pipeline is comprised of approximately 19 drug candidates present in different stages of development.
- Some of pipeline drug candidates under clinical trial phases of development include Omalizumab, Dupilumab, Viaskin etc, that contribute to the growth of the market. For instance, BioLingus Inc. is utilizing a technology called BioLingus technology, which is a micro-encapsulation process that delivers macromolecules such as peptides and proteins and is particularly effective for sublingual immunotherapy for the treatment of peanut allergy.

- Most of the drug development molecules in the pipeline are under the pre-clinical drug development stage.
- Various technological advancements characterized peanut allergy therapeutics pipeline growth. The increase in the number of patents approvals and improvements in technologies are the major factors driving the growth of the pipeline.
- Some of the other factors strengthening the pipeline growth include; positive clinical as well as preclinical results of various drug candidates and support from various health organizations such as educational institutes and National Institutes of health.

## I would like to order

Product name: Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

Product link: <https://marketpublishers.com/r/PF0248FF7F35EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PF0248FF7F35EN.html>